# TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study

> **NCT05882370** · PHASE2 · RECRUITING · sponsor: **Fei Gao** · enrollment: 30 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Cadonilimab
- **PROCEDURE:** transjugular intrahepatic portosystemic shunt (TIPS)

## Key facts

- **NCT ID:** NCT05882370
- **Lead sponsor:** Fei Gao
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-01
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-08-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05882370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05882370, "TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05882370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*